CNX-774

Overview

CNX-774 is an orally active, irreversible and selective BTK inhibitor, with an IC 50 of < 1 nM. CNX-774 specifically targets Cysteine 481 of Btk for covalent modification.

Application

Products | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Rheumatoid Arthritis | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Arthritis | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > Btk

Product Information

• Catalog No.: HY-13943
• CAS No.: 1202759-32-7
• Molecular Formula: C26H22FN7O3
• Molecular Weight: 499.50
• Purity: 99.92%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.5 mg/mL (5.01 mM); Clear solution
• Availability: In-stock

Source

Original product source